Support Alert

Class 4 Medicines Defect Information: Rifadin (rifampicin) 150mg Capsules (MDR 127-09/19)

Aventis Pharma Limited t/a Sanofi has informed the Medicines and Healthcare products Regulatory Agency (MHRA) that a change to the Patient Information Leaflet, concerning possible side effects for Rifadin (rifampicin) 150mg Capsules, has not been implemented by the required timeline.

Loading...